About Iterum Therapeutics
Iterum Therapeutics is a company based in Dublin (Ireland) founded in 2015. Iterum Therapeutics has raised $78.1 million across 4 funding rounds from investors including New Leaf Venture Partners, RA Capital and Frazier Healthcare Partners. The company has 9 employees as of December 31, 2024. Iterum Therapeutics offers products and services including Sulopenem and ORLYNVAH. Iterum Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
- Headquarter Dublin, Ireland
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iterum Therapeutics Plc
-
Annual Revenue
Not available
-
Net Profit
-$24.77 M (USD)35.44as on Dec 31, 2024
-
EBITDA
-$18.41 M (USD)59.73as on Dec 31, 2024
-
Total Equity Funding
$78.1 M (USD)
in 4 rounds
-
Latest Funding Round
$2.83 M (USD), Post-IPO
Jul 02, 2020
-
Investors
New Leaf Venture Partners
& 10 more
-
Employee Count
9
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Iterum Therapeutics
Iterum Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ITRM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Iterum Therapeutics
Iterum Therapeutics offers a comprehensive portfolio of products and services, including Sulopenem and ORLYNVAH.
Oral and IV drug for treating multi-drug resistant infections.
Medicine targeting gram-negative bacterial infections in various settings.
People of Iterum Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Iterum Therapeutics
Iterum Therapeutics has successfully raised a total of $78.1M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.83 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Iterum Therapeutics
Iterum Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, RA Capital and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in biotech startups are made by Arix Bioscience.
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked |
Investor details for Iterum Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Iterum Therapeutics
Investment portfolio details for Iterum Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Iterum Therapeutics
Detailed financials for Iterum Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iterum Therapeutics Comparisons
Peer comparison for Iterum Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Iterum Therapeutics
Iterum Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of Iterum Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iterum Therapeutics
Complete news archive for Iterum Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iterum Therapeutics
Iterum Therapeutics was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Iterum Therapeutics is headquartered in Dublin, Ireland.
Iterum Therapeutics is a funded company, having raised a total of $78.1M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Iterum Therapeutics is 9.
Developer of antibiotics for MDR infections. Its first product is a novel anti-infective substance, Sulopenem, that has shown in-vitro activity against a variety of gram-negative, gram-positive, and anaerobic bacteria that resist other antibiotics. The product pipeline includes Sulopenem etzadroxil - probenecid to treat UTI and cUTI, Sulopenem for cUTI, and complicated intra-abdominal infections.
Iterum Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Iterum Therapeutics offers Sulopenem and ORLYNVAH.
Yes, Iterum Therapeutics is publicly traded on NASDAQ under the ticker symbol ITRM.
Iterum Therapeutics has 11 investors. Key investors include New Leaf Venture Partners, RA Capital, Frazier Healthcare Partners, Canaan, and Arix Bioscience.
The ticker symbol of Iterum Therapeutics is ITRM on NASDAQ.